In our study, those endometrial cancers with an ARID1A mutation showed elevated levels of TILs and PD-L1 scores, and in contrast, cases with CTNNB1 mutated showed low levels of these two biomarkers, which would support this hypothesis. The gene discussed is ARID1A; the disease is endometrial cancer.